A new publication on etelcalcetide appeared on August 17, 2026. The study, titled "Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease," was published in Expert Review of Pharmacoeconomics & Outcomes Research.
The paper presents a cost-effectiveness comparison among etelcalcetide, paricalcitol, and cinacalcet for patients with secondary hyperparathyroidism related to chronic kidney disease. No specific findings, outcome measures, or conclusions were provided beyond the publication title and journal listing.
This entry reflects only the appearance of the publication and its stated subject matter. Readers interested in the full scope of the analysis, including methodology and results, should consult the original article directly through the source link.
For additional background on etelcalcetide, including its approved use and general profile, readers can refer to the compound overview.